Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Audioboom paints upbeat outlook after solid Q1

(Sharecast News) - Shares in Audioboom fell sharply on Wednesday despite the podcast company predicting that it will "at least" meet financial targets this year after a solid first quarter with earnings rising strongly. Adjusted EBITDA in the three months to 31 March totalled $0.7m, a tenfold increase over the year before.

Revenues rose by just 1% to $17.3m, which the company said reflects its focus on higher-margin sales.

"That focus on higher quality revenue led us to relinquish a number of low-performing contracts during the quarter. We replaced them with higher-margin revenue - so while our revenue growth is in the low single figures, it is significantly healthier, and it is exactly where we expected it to be," said chief executive Stuart Last.

Top-line growth is expected to accelerate over the coming quarters, with the first quarter historically being the seasonal low point for revenue.

Average revenue per 1,000 downloads was up 17% over last year at $60.83, while the average total brand advertiser count rose 14% to 8,974.

"The company is confident it will at least meet its revenue and adjusted EBITDA profit goals for 2025, and has made significant progress with contracted revenue of more than US$63m for the year through advanced advertising bookings," Audioboom said.

The company also added that it expects "minimal impact" from recently announced US tariffs due to the production and sale of its inventory being within specific territories.

Shares were down 5.8% at 410p in early deals.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.